PharmaTher Holdings Ltd.PHRM.CN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · CSE · Canada · pharmather.com
Toronto-based specialty pharmaceutical company focused on personalized medicines, specifically peptides and psychedelics, leveraging its MEDBOTX 3D-printing platform and AI-driven formulation tools for patient-specific dosing and delivery formats. Also trades OTCQB:PHRRF.
Key ratios
ROA
-59.2%TTM
2025
-48.5%2024
-42.8%2023
-26.8%
ROE
-125.4%TTM
2025
-92.2%2024
-80.4%2023
-74.4%
Recent news
PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
PharmaTher Launches M3DICINES™ National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform
PharmaTher Collaborates with Craft Health to Evaluate CraftMake GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
PharmaTher Launches Personaliz3D Peptides to Advance Personalized Peptide Care
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Track PHRM.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer